Arcutis Biotherapeutics, Inc. Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc.

ARQT

Rang in aandelen #4010
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to... Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Aandeelprijs
$32.29
Laatst gesynchroniseerd: 2026-10-19
Marktkapitalisatie
$4.06B
Verandering (1 dag)
12.02%
Verandering (1 jaar)
54.62%
Land
US
Handel Arcutis Biotherapeutics, Inc. (ARQT)

Categorie

Healthcare
Dividendrendementgeschiedenis voor Arcutis Biotherapeutics, Inc. (ARQT)
Het dividendrendement (TTM) van Arcutis Biotherapeutics, Inc. (aandelsymbool: ARQT) per 2023-12-31 is: 0.00%
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Arcutis Biotherapeutics, Inc. (ARQT) van 2017 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten
Bedrijf Dividendrendement Land
0.00%
US
0.00%
US
2.17%
AU
0.00%
CH
0.00%
NL